TY - JOUR T1 - Platelet Activation by Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Patient Serum is Blocked by COX, P2Y<sub>12</sub> and Kinase Inhibitors JF - medRxiv DO - 10.1101/2021.04.24.21255655 SP - 2021.04.24.21255655 AU - Christopher W. Smith AU - Caroline Kardeby AU - Ying Di AU - Gillian C. Lowe AU - William A. Lester AU - Steve P. Watson AU - Phillip L.R. Nicolson Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/27/2021.04.24.21255655.abstract N2 - Background The novel coronavirus SARS-CoV-2 has caused a global pandemic. Vaccines are an important part of the response. Although rare, unusual thrombotic events and thrombocytopenia in recipients 4–16 days after vaccination with the AstraZeneca AZD1222 have been reported. This syndrome of vaccine-induced immune thrombotic thrombocytopenia (VITT) clinically resembles heparin induced thrombocytopenia (HIT), which is caused by platelet activating antibodies against platelet factor 4 (PF4). Here, we investigate the effect of serum from patients with VITT on platelet activation, and assess the ability of clinically available therapeutics to prevent platelet activation.Methods Aggregation responses of healthy donor washed platelets were assessed in response to serum from patients with VITT pre- and post-intravenous immunoglobulin (IVIg) treatment and in the presence of anti-FcγRIIA blocking IV.3 F(ab), anti-platelet drugs and kinase inhibitors.Findings Four patients (21 - 48 years old) presented with thrombosis (three patients: cerebral venous sinus thrombosis, one patient: ischemic stroke) and thrombocytopenia 10-14 days after AZD1222 vaccination. All patients tested positive for anti-PF4 antibody despite no prior heparin exposure. Serum from patients with VITT, but not healthy donor controls, induced platelet aggregation, which was abrogated following IVIg treatment. Aggregation to patient sera was blocked by IV.3 F(ab) which targets FcγRIIA, and inhibitors of Src, Syk and Btk kinases downstream of the receptor. Anti-platelet therapies indomethacin and ticagrelor also blocked aggregation.Interpretation In conclusion, serum from patients with VITT activates platelets via the FcγRIIA, which can be blocked in vitro by anti-platelet therapies suggesting possible new therapeutic interventions for this rare syndrome.Funding This work was supported by an Accelerator Grant (AA/18/2/34218) from the British Heart Foundation (BHF).Key pointsSerum from patients with VITT activates platelets via the FcγRIIA.Platelet activation by serum from patients with VITT can be blocked by COX, P2Y12, Src, Syk and Btk inhibition.Competing Interest StatementPLRN and SPW have received research grants from Novartis, Principia and Rigel Pharmaceuticals. PLRN has had honoraria from Bayer.Funding StatementThis work was supported by an Accelerator Grant (AA/18/2/34218) from the British Heart Foundation (BHF). CK is supported by the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Actions Individual Fellowship grant agreement [No 893262], project PAELLA. SPW holds a BHF Chair (CH03/003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients presenting with thrombosis and thrombocytopenia, occurring after AZD1222 vaccination were recruited. Collection of blood from these patients (including those lacking capacity) was approved under research ethics granted to the University of Birmingham Human Biomaterial Resource Centre (North West Haydock Research Ethics Committee, reference: 15/NW/0079, amendment 3, 19/11/2018). Ethical approval for collecting blood from healthy volunteers was granted by Birmingham University Internal Ethical Review Committee (reference: ERN_11-0175, assessed 22/3/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data will not be made available. ER -